2018 Benicar Lawsuit News: A June 2018 press release from Daiichi Sankyo Company announced that more than 97% of plaintiffs in federal and state courts have agreed to a $358 million Benicar lawsuit settlement.

The blood pressure medication Benicar has been linked to severe gastrointestinal problems and even death, leading thousands of people to file product liability lawsuits against Daiichi Sankyo. The pharmaceutical company announced a potential settlement in August 2017, and in June 2018 it finalized the settlement amount after 97% of plaintiffs opted in. While a handful of cases are still awaiting trial, Benicar litigation is effectively considered closed to new lawsuits.

Why People Were Filing Benicar Lawsuits

Benicar is an angiotensin II receptor antagonist (ARB) used to treat high blood pressure and reduce the risk of heart attack. First approved by the U.S. Food and Drug Administration (FDA) in 1995, studies have shown a link between Benicar’s active ingredient, olmesartan, and certain severe side effects. The most notable is sprue-like enteropathy, a serious gastrointestinal condition that can lead to significant weight loss and, in some cases, death.

Patients or their surviving family members have filed lawsuits against Daichii Sankyo for failing to warn them about dangerous Benicar side effects. The primary complaint by these plaintiffs is that Daiichi Sankyo either knew or should have known about these possible injuries, and that the drugmaker failed to inform customers of these potential dangers.

Benicar and Sprue-Like Enteropathy

Several medical studies have investigated the connection between Benicar and sprue-like enteropathy, a severe form of chronic diarrhea that can lead to substantial weight loss and intestinal problems. A 2012 report from the Mayo Clinic was among the first to find a connection, with additional studies published in 2013 and 2014.

Injury reports and studies led the FDA to approve label changes for Benicar, Benicar HCT, Azor and Tribenzor in 2013. The new warning labels warned that patients who developed sprue-like enteropathy symptoms should stop taking Benicar if no other cause for their condition could be found. Other related side effects have also been listed in Benicar lawsuits.

Benicar Lawsuit Claims

  • Serious gastrointestinal injuries
  • Olmesartan Associated Enteropathy (“OAE”)
  • Sprue-like enteropathy
  • Villous atrophy, blunting, or damage
  • Inflammation
  • Nausea
  • Vomiting
  • Chronic diarrhea
  • Malnutrition
  • Dehydration
  • Atrophy
  • Kidney failure
  • Weight loss
  • Abdominal and gastrointestinal pain
  • Colitis
  • Gastritis
  • Death

Brands Named in Benicar Lawsuits

While Benicar is the most common brand name, several different drugs contain the active ingredient olmesartan medoxomil under other names:

  • Benicar – olmesartan medoxomil
  • Benicar HCT – olmesartan medoxomil + hydroclorothiazide
  • Azor – olmesartan medoxomil + amlodipine
  • Tribenzor – olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec – olmesartan medoxomil sold in Europe and Canada

Benicar Litigation

MDL 2606 – District of New Jersey

Lawsuits related to Benicar and other olmesartan drug products created by Daiichi Sankyo have been centralized into a multidistrict litigation (MDL) case in the United States District Court for the District of New Jersey. At its peak, the Benicar MDL had more than 2,300 cases assigned to it, each of which was filed by an individual who suffered from side effects of the blood pressure drug (or a surviving family member).

In June 2018, most of the lawsuits in the Benicar MDL were resolved after 97% of participants agreed to participate in the settlement proposed by Daichii Sankyo in August 2017. A handful of plaintiffs who rejected the settlement are still pursuing their cases in the District of New Jersey.

Benicar Settlement

Million Settlement fund established

On August 1, 2017, Daiichi Sankyo agreed to pay $300 million to settle all cases if 95% of all claimants opted in. The amount was later increased in May 2018 to $358 million after 97% of claimants opted in, accounting for more than 2,230 of the 2,300 cases that were part of the MDL.

Although the pharmaceutical company settled, Daichii Sankyo did not admit liability, issuing the following statement: “We believe a settlement is in the best interest of all, and will allow us to continue our focus on bringing to market innovative medicines that help people live healthy and meaningful lives.”

Department of Justice Investigation and Settlement

In 2015, Daichii Sankyo paid $40 million to the U.S. Department of Justice to settle an allegation that it had made illegal payments to doctors in return for prescribing Benicar and other drugs to their patients from 2005 through 2011.

Benicar Lawsuit FAQs

Some of the most common questions related to Benicar lawsuits are answered below.

Am I Eligible to File a Benicar Lawsuit?

At this time, more than 97% of outstanding Benicar lawsuits have agreed to settle according to the master settlement agreement proposed by Daichii Sankyo in August 2017. While a handful of cases are still working their way through federal courts, most lawyers are no longer taking new Benicar cases.

What Compensation Is Available for Benicar Lawsuits?

The Benicar settlement totals $358 million and covers more than 2,200 cases. However, not all of the plaintiffs who file a lawsuit will receive the same amount. How much each person receives will be determined by various factors, including:

  • Medical costs related to their Benicar side effects
  • Pain and suffering caused by the drug
  • Other factors determined by the settlement agreement

Plaintiffs whose case is part of the settlement should talk with their lawyer about what they expect to receive as part of the settlement.